Cellab CDMO, Cellab's new activity
The Andorran biotech company is working to obtain Good Manufacturing Practices (GMP) during the first half of 2023
Cellab expects to complete the path initiated in 2019 to launch a new line of activity this 2023, focused on the cell therapies manufacture and R&D development for third parties, with tailor-made services as CDMO from Andorra and for the whole of Europe. To carry out the implementation of the GMP, Cellab relies on the consultancy of Gradocell.
Cellab offers a wide range of services that are tailored to the needs and timescales of the client, from R&D to GMP production, QC laboratory services, GMP Cell Bank, covering all the needs that the client may have.
Cellab CDMO has an expert team of scientists who put at your disposal all the knowledge to manufacture advanced therapy drugs at a competitive price.
Due to the continued activity as tissue and cell bank AABB accredited, Cellab has access to biological starting material from various sources, such as adipose tissue and blood and umbilical cord tissue, which comply with European donation guidelines.
For more information about Cellab CDMO, please visit us at www.cellab.com or email us at info@cellab.com